Search the web
Welcome, Guest
[Sign Out, My Account]
EDGAR_Online

Quotes & Info
Enter Symbol(s):
e.g. YHOO, ^DJI
Symbol Lookup | Financial Search
ACUR > SEC Filings for ACUR > Form 8-K on 27-May-2014All Recent SEC Filings

Show all filings for ACURA PHARMACEUTICALS, INC

Form 8-K for ACURA PHARMACEUTICALS, INC


27-May-2014

Other Events


Item 8.01 Other Events

On May 27, 2014 we issued a press release announcing that the US Food and Drug Administration (FDA) advised us that the data from our intranasal abuse liability study AP-ADF-301 (Study 301) for our AVERSION® hydrocodone bitartrate with acetaminophen (hydrocodone/APAP) product candidate are insufficient to support an intranasal abuse deterrence claim and questioned whether the intranasal route is a relevant route of abuse for hydrocodone/APAP products and recommended we identify variables that could have impacted the findings from Study 301 before considering or conducting an additional intranasal abuse liability study on our AVERSION hydrocodone/APAP product. The press release is attached hereto and filed as Exhibit 99.1.

  Add ACUR to Portfolio     Set Alert         Email to a Friend  
Get SEC Filings for Another Symbol: Symbol Lookup
Quotes & Info for ACUR - All Recent SEC Filings
Copyright © 2014 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service
SEC Filing data and information provided by EDGAR Online, Inc. (1-800-416-6651). All information provided "as is" for informational purposes only, not intended for trading purposes or advice. Neither Yahoo! nor any of independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. By accessing the Yahoo! site, you agree not to redistribute the information found therein.